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ABSTRACT
Objective  To compare the efﬁ  cacy and safety of 
treatment with inﬂ  iximab plus methotrexate with 
methotrexate alone in methotrexate-naive patients with 
active psoriatic arthritis (PsA).
Methods  In this open-label study, patients 18 years and 
older with active PsA who were naive to methotrexate 
and not receiving disease-modifying therapy (N=115) 
were randomly assigned (1:1) to receive either inﬂ  iximab 
(5 mg/kg) at weeks 0, 2, 6 and 14 plus methotrexate 
(15 mg/week); or methotrexate (15 mg/week) alone. 
The primary assessment was American College of 
Rheumatology (ACR) 20 response at week 16. Secondary 
outcome measures included psoriasis area and severity 
index (PASI), disease activity score in 28 joints (DAS28) 
and dactylitis and enthesitis assessments.
Results  At week 16, 86.3% of patients receiving 
inﬂ  iximab plus methotrexate and 66.7% of those receiving 
methotrexate alone achieved an ACR20 response 
(p<0.02). Of patients whose baseline PASI was 2.5 or 
greater, 97.1% receiving inﬂ  iximab plus methotrexate 
compared with 54.3% receiving methotrexate alone 
experienced a 75% or greater improvement in PASI 
(p<0.0001). Improvements in C-reactive protein levels, 
DAS28 response and remission rates, dactylitis, fatigue 
and morning stiffness duration were also signiﬁ  cantly 
greater in the group receiving inﬂ  iximab. In the inﬂ  iximab 
plus methotrexate group, 46% (26/57) had treatment-
related adverse events (AE) and two patients had serious 
AE, compared with 24% with AE (13/54) and no serious 
AE in the methotrexate-alone group.
Conclusions  Treatment with inﬂ  iximab plus 
methotrexate in methotrexate-naive patients with 
active PsA demonstrated signiﬁ  cantly greater ACR20 
response rates and PASI75 improvement compared with 
methotrexate alone and was generally well tolerated.
This trial is registered in the US National Institutes 
of Health clinicaltrials.gov database, identiﬁ  er 
NCT00367237.
Psoriatic arthritis (PsA) is an inﬂ  ammatory arthrop-
athy associated with skin psoriasis.1 The estimated 
prevalence of psoriasis is 1–3% of the population, 
and the reported prevalence of PsA among patients 
with psoriasis ranges from 6% to 48%.1–4 PsA has 
a substantial impact on patients’ lives1 5–9 and is 
associated with persistent inﬂ  ammation,6 10 pro-
gressive joint damage leading to functional disabil-
ity5 10 and reduced life expectancy.1 7
Methotrexate is often used as the primary treat-
ment for PsA, despite a paucity of evidence demon-
strating its clinical beneﬁ  t.10–12 In fact, to date, only 
two randomised controlled trials of methotrexate 
in PsA have been published, and neither was suf-
ﬁ  ciently powered to assess the clinical beneﬁ  t.13 
14 Black et al13 demonstrated in 21 patients with 
long-term disease that methotrexate injections at 
10-day intervals provided some improvement in 
joint symptoms and decreased area of skin involve-
ment versus placebo. Willkens et al14 compared oral 
pulse methotrexate therapy with placebo in 37 PsA 
patients with long-term disease over 12 weeks and 
found methotrexate to be statistically superior to 
placebo only in physician assessment of arthritis 
activity and in the reduction of surface area affected 
by psoriasis.
Tumour necrosis factor (TNF) inhibitors are an 
established treatment for both skin and locomotor 
system manifestations of PsA.10 15–20 The efﬁ  cacy 
of inﬂ  iximab for reducing symptoms and halting 
radiographic progression was ﬁ   rst established in 
the placebo-controlled Inﬂ  iximab  Multinational 
Psoriatic Arthritis Controlled Trial (IMPACT) and 
IMPACT 2 studies.21–24 To date, evidence to sup-
port any superiority of TNF inhibitors plus metho-
trexate over methotrexate alone is lacking.10 12
The present open-label study compared the efﬁ  -
cacy and safety of inﬂ  iximab in combination with 
methotrexate to methotrexate alone in methotrex-
ate-naive subjects with active polyarticular PsA.
METHODS
Patient population
Enrolled patients were 18 years or older, rheuma-
toid factor negative, and had psoriasis in combina-
tion with peripheral articular disease with at least 
one of the following four characteristics for 3 or 
more months before screening: distal interphalan-
geal joint involvement; polyarticular arthritis in the 
absence of rheumatoid nodules; arthritis mutilans; 
or asymmetric peripheral arthritis. Active disease 
was deﬁ  ned as the presence of ﬁ  ve or more swol-
len joints, ﬁ  ve or more tender joints and at least 
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test results and vital signs at all visits. Investigators assessed AE 
severity and relationship to study treatment.
Statistical analysis
It was determined that a sample size of 216 (108 per treatment 
group) would allow detection of a 20% difference in the propor-
tion of patients achieving an ACR20 response with 85% power. 
This assessment was made assuming the use of a χ2 test with a 
signiﬁ  cance level of 0.05 and assuming a 50% response for inf-
liximab plus methotrexate and a 30% response for methotrexate 
alone. To allow for dropouts (the anticipated dropout rate was 
10%), up to 243 subjects were to be enrolled.
The intent-to-treat (ITT) population included all randomly 
assigned subjects who received at least one dose of study medica-
tion and had baseline as well as at least one post-baseline efﬁ  cacy 
assessment. The efﬁ  cacy-evaluable per-protocol (PP) population 
included all of the subjects who followed the protocol and had 
both baseline and week 16 efﬁ  cacy data. Protocol violators were 
identiﬁ  ed and the PP population decided before database lock 
based on a blinded review of the data. The ITT population was 
the primary population for the superiority analyses. As the rate 
of exclusion due to protocol violations exceeded 5% in each 
treatment group, a PP population was also analysed.
A χ2 test was used to compare the proportions of subjects 
achieving an ACR20 response at week 16. To limit bias and 
capture the difference in response between the inﬂ  iximab plus 
methotrexate and methotrexate-alone groups, the study protocol 
speciﬁ  ed that non-responders were patients: with missing ACR 
data; who withdrew due to lack of efﬁ  cacy or loss of response; 
who received additional treatments or study medication doses 
outside the protocol; and who underwent surgical joint proce-
dures. This method was chosen over non-responder imputation, 
which is criticised in the statistical literature for being biased 
and invalid even under highly restrictive assumptions about pat-
terns of missingness, such as data that are missing completely 
at random.26 27 28
However, for the purpose of comparison with other studies, 
the non-responder imputation statistics for ACR20 and PASI75 
at week 16 plus MDA at each study visit are also provided here. 
These post-hoc analyses were requested during the journal peer-
review process.
Change from baseline in the PASI score was compared 
between treatment groups using analysis of covariance with 
baseline values as the covariate. Similarly, change from baseline 
in DAS28 and all other secondary endpoints were compared 
using analysis of covariance with baseline values as the covari-
ate, unless there were analysis methods more appropriate for 
the observed distribution. The difference in EULAR response 
between groups at each visit was assessed by testing between 
treatments in mean ridit scores.
The safety population included all subjects who took at least 
one study dose. No formal statistical testing was performed to 
compare the safety data between treatment groups.
RESULTS
Patient characteristics
As a result of the restrictive inclusion/exclusion criteria, recruit-
ment was slow (May 2006–March 2008) and was halted at 115 
subjects: 57 randomly assigned to inﬂ  iximab plus methotrexate, 
58 to methotrexate alone (ﬁ  gure 1). Four subjects in the metho-
trexate group withdrew consent before receiving study treat-
ment. Thirty subjects were excluded from the PP efﬁ  cacy analysis 
for protocol violations; of these, 10 inﬂ  iximab plus methotrexate 
one of the following: erythrocyte sedimentation rate (ESR) 28 
mm/h or greater; C-reactive protein (CRP) 15 mg/l or greater, 
or morning stiffness for 45 min or more. Patients were naive 
to methotrexate, inﬂ   iximab and other biological agents, and 
those with known contraindications to methotrexate or inﬂ  ix-
imab were excluded from participation. Leﬂ  unomide and other 
disease-modifying antirheumatic drugs (DMARD) could not be 
used within 6 months or 12 weeks, respectively, before study 
screening. Tacrolimus and ciclosporin could not be used in the 
4 weeks before screening. The use of non-steroidal anti-inﬂ  am-
matory drugs (NSAID) and oral steroids (maximum dose 10 mg/
day of prednisone or equivalent) was allowed if the dose was 
stable within 4 weeks before screening and kept stable through-
out the study. Patients could not be included if they had active 
or untreated latent tuberculosis, opportunistic or other uncon-
trolled infections, a history of lymphoproliferative disease or 
malignancy in the 5 years before screening, or any other signiﬁ  -
cant and uncontrolled disorder. A tuberculin skin test and chest 
x-ray were performed during screening within 30 days of receiv-
ing a ﬁ  rst inﬂ  iximab infusion and/or dose of methotrexate.
The study was carried out according to the Declaration of 
Helsinki and conducted in accordance with the International 
Conference on Harmonisation Good Clinical Practice Guidelines. 
The study protocol was approved by the ethics committee at 
each of the participating study sites. All patients provided writ-
ten informed consent before participating in any study-related 
activities.
Study design
This was a phase IIIB, randomised, prospective, open-label 
study conducted in 25 centres in Europe, the Middle East, South 
Africa and Turkey. Subjects were randomly assigned to one of 
two treatment arms (1:1) to receive either inﬂ  iximab 5 mg/kg 
infusions at weeks 0, 2, 6 and 14 plus methotrexate 15 mg/week, 
or methotrexate 15 mg/week alone. In both groups, methotrex-
ate could be increased to 20 mg/week at week 6 if improve-
ment of 20% in the American College of Rheumatology (ACR) 
response criteria (ACR20) was not achieved. Assessments were 
performed at weeks 2, 6 and 14. The ﬁ  nal study visit was at 
week 16.
Outcome measures
The primary efﬁ   cacy endpoint was the proportion of sub-
jects achieving an ACR20 response from baseline at week 16. 
Secondary efﬁ  cacy endpoints included proportions of patients 
with ACR50 and ACR70 responses, 75% improvement in 
the psoriasis area and severity index (PASI) in subjects whose 
baseline PASI was 2.5 or greater, and European League Against 
Rheumatism (EULAR) response. All rheumatologists were 
trained to perform PASI scoring. Change from baseline was 
investigated for the individual ACR core domains (ie, physician 
and patient global assessment of disease activity, patient self-re-
ports of pain and disability, and CRP), PASI and disease activity 
score in 28 joints (DAS28) scores, number of digits with dactyli-
tis, Maastricht ankylosing spondylitis enthesitis score, fatigue 
(visual analogue scale), duration of morning stiffness, ESR and 
CRP. As measures of clinical remission/minimal disease activ-
ity (MDA), the following outcomes were reported at week 16: 
absence of swollen joints, tender joints, enthesitis and dactyli-
tis; normal CRP; DAS28 remission (<2.6); PASI90 response; and 
published criteria for MDA.25 Axial disease was not assessed.
Safety assessments included adverse event (AE) reporting, 
changes in physical examination ﬁ   ndings, clinical laboratory 
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group and 10 patients in the methotrexate-alone group received 
a dose increase to 20 mg at week 6.
In the ITT analysis, an ACR20 response at week 16 was 
achieved in 44 of 51 patients (86.3%) in the inﬂ  iximab plus 
methotrexate group compared with 32 of 48 patients (66.7%) 
in the methotrexate-alone group (p=0.021). Analysis using the 
PP population yielded almost identical results, which were also 
statistically signiﬁ  cant (p=0.039). In the non-responder imputa-
tion analysis, week 16 ACR20 response rates were 78.6% in the 
inﬂ  iximab plus methotrexate group and 59.3% (p=0.028) in the 
methotrexate-alone group. The difference in ACR20 response 
between treatment groups was statistically signiﬁ  cant at every 
study visit in both the ITT and PP populations. ACR50 and 
ACR70 response rates at week 16 were also signiﬁ  cantly greater 
in the inﬂ  iximab plus methotrexate group at most study visits 
(ﬁ  gure 2).
In patients with a PASI of 2.5 or greater at baseline, a PASI75 
response at week 16 was observed in 33 of 34 patients (97.1%) 
receiving inﬂ  iximab plus methotrexate compared with 19 of 35 
patients (54.3%) receiving methotrexate alone (p<0.0001). In the 
non-responder imputation analysis, week 16 PASI75 response 
rates were 91.7% in the inﬂ  iximab plus methotrexate group 
and 47.5% (p=0.00004) in the methotrexate-alone group. The 
change from baseline in PASI score was statistically signiﬁ  cant at 
every time point. By week 16, the mean reduction in PASI score 
was 93.3% for patients treated with inﬂ  iximab plus methotrex-
ate and 67.4% for patients treated with methotrexate alone 
(p=0.0029).
The mean DAS28 at week 16 improved by 56.5% (mean 
change –2.95±1.05) in inﬂ   iximab plus methotrexate patients 
compared with 29.7% (mean change –1.51±1.31) in methotrex-
ate-alone patients (p<0.0001). The EULAR response at week 16 
was achieved in 50 of 51 patients (98%) receiving inﬂ  iximab 
plus methotrexate compared with 35 of 48 patients (72.9%) 
receiving methotrexate alone (p<0.0001).
A median reduction of two digits with dactylitis was 
observed at week 16 in the inﬂ  iximab plus methotrexate group, 
while no reduction was observed in the methotrexate-alone 
group (p=0.0006). Between-group differences were statistically 
signiﬁ  cant at all time points. A median reduction of two sites 
patients and 11 methotrexate-alone patients did not complete 
the study as scheduled (week 16 efﬁ  cacy data missing).
At baseline, the treatment groups were generally similar and 
well balanced. The numerical gender difference was not statis-
tically signiﬁ  cant (p=0.15). Subject assessment of fatigue and 
morning stiffness was signiﬁ  cantly different between the two 
groups (tables 1 and 2).
Efﬁ  cacy results
Four inﬂ  iximab infusions were received by 86% (49/57) of sub-
jects in the combination treatment arm. The mean infused dose 
was 389.4 mg, corresponding to approximately 5 mg/kg based 
on the mean body weight (78.2 kg). The 16 planned doses of 
methotrexate were received by 64.9% of inﬂ  iximab plus metho-
trexate subjects and 79.6% of methotrexate-alone subjects. The 
average weekly dose of methotrexate was 14.6 mg in the inﬂ  ix-
imab plus methotrexate group and 15.4 mg in the methotrexate-
alone group. One patient in the inﬂ  iximab plus methotrexate 
Figure 1  Disposition of study subjects. AE, adverse events; IFX, 
inﬂ  iximab; MTX, methotrexate.
Table 1  Subject demographics and baseline disease characteristics (ITT population)
Subject characteristics
Inﬂ  iximab plus 
methotrexate (n=56) Methotrexate (n=54)*
Male, n (%) 27 (48.2) 33 (61.1)
Female, n (%) 29 (51.8) 21 (38.9)
Mean age±SD, years 40.1±12.3 42.3±10.5
White, n (%) 52 (92.9) 49 (90.7)
Asian, n (%) 3 (5.4) 5 (9.3)
Multiracial, n (%) 1 (1.8) 0 (0)
Mean BMI±SD, kg/m2 26.9±5.1 28.1±5.3
Mean duration of PsA±SD, years 2.8±2.6 3.7±2.7
Mean swollen joint count±SD 15.1±10.1 14.3±9.5
Mean tender joint count±SD 21.1±13.3 20.1±11.2
Mean number of digits with dactylitis±SD 3.3±4.2 3.1±4.2
Mean number of assessment sites with enthesitis±SD (MASES) 2.4±3.0 2.7±2.8
Mean DAS28±SD 5.16±1.1 5.07±1.2
Mean fatigue/tiredness score±SD, VAS rating 55.7±22.0 53.0±17.4
Mean morning stiffness±SD, h 1.46±0.87 1.13±0.58
Mean HAQ–DI score±SD 1.54±0.62 1.49±0.66
Mean PASI±SD 8.27±10.2 11.62±12.5
*Except for PASI score, where n=53.
BMI, body mass index; DAS28, disease activity score in 28 joints; HAQ–DI, health assessment questionnaire–disability index; ITT, 
intent to treat; MASES, Maastricht ankylosing spondylitis enthesitis score; PASI, psoriasis area and severity index; PsA, psoriatic 
arthritis; VAS, visual analogue scale.
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with enthesitis was observed at week 16 in the inﬂ  iximab plus 
methotrexate group compared with a reduction of one site in 
the methotrexate-alone group (p=0.082). Between-group differ-
ences were not statistically signiﬁ  cant at any time point.
The reduction from baseline in fatigue score was greater in 
the inﬂ   iximab plus methotrexate group compared with the 
methotrexate-alone group at all time points. At week 16, the 
mean reduction from baseline was 70.8% in the inﬂ  iximab plus 
methotrexate group compared with 44.0% in the methotrex-
ate-alone group (p=0.0003). At week 16, the median change 
in the duration of morning stiffness was –0.92 h with com-
bination treatment versus –0.50 h with methotrexate alone 
(p=0.0015).
Changes from baseline in all ACR core domains were signiﬁ  -
cantly different between the treatments at all time points (table 3). 
Overall, patients receiving inﬂ  iximab plus methotrexate showed 
more profound levels of disease suppression, as illustrated by 
DAS28 remission rates, absence of swollen or tender joints, normal 
CRP and PASI90 responses (ﬁ  gure 3A). The proportion of patients 
with MDA at each visit was signiﬁ  cantly greater for patients treated 
with combination therapy (ﬁ  gure 3B).
Safety results
The incidence of AE was higher in patients receiving inﬂ  iximab 
plus methotrexate versus methotrexate alone. Most AE were 
mild or moderate. One AE in each group was considered severe: 
increased transaminases in the inﬂ   iximab plus methotrexate 
group and renal colic in the methotrexate-alone group. In the 
inﬂ  iximab plus methotrexate group, 26 of 57 subjects (45.6%) 
had one or more treatment-related AE, and in the methotrex-
ate-alone group, 13 of 54 subjects (24.1%) had one or more 
treatment-related AE. The most frequent treatment-related 
AE involved hepatic enzyme increases. These abnormalities 
occurred at similar incidence in both treatment groups and were 
likely to be treatment related (table 4).
Two serious AE were reported, both in the inﬂ  iximab plus 
methotrexate group, and no deaths occurred. One subject experi-
enced an infusion-related reaction with dyspnoea and erythema 
of moderate severity during the third infusion, which resolved 
following dexamethasone administration, but the patient was 
withdrawn from further treatment. Another subject was hos-
pitalised twice for investigation of a suspected lung tumour, 
and inﬂ   iximab was permanently discontinued following the 
ﬁ  rst hospital visit. Pulmonary tuberculosis was diagnosed at the 
second hospital visit and anti-tuberculosis treatment was initi-
ated. Re-evaluation of a prestudy chest x-ray revealed a lesion 
Table 2  Previous medications by treatment group*
Previous medication
Inﬂ  iximab plus 
methotrexate 
n=57
Methotrexate 
n=58
NSAID
Salicylates 5.3% 1.7%
Propionic acid derivatives 1.7% 5.3%
Acetic acid derivatives 33.3% 32.8%
Oxicam derivatives 28.1% 19.0%
DMARD (sulfasalazine n=22, chloroquine n=2, 
gold n=1)
22.8% 15.5%
Corticosteroids 15.8% 15.5%
Ciclosporin 5.3% 12.1%
Retinoids 5.3% 1.7%
* Previous medications were used by more than 5% of total patients.
DMARD, disease-modifying antirheumatic drugs; NSAID, non-steroidal anti-
inﬂ  ammatory drugs.
Figure 2  Proportion of patients achieving ACR20 (A), ACR50 (B) and 
ACR70 (C) response over time (ITT population). ACR, American College 
of Rheumatology; IFX, inﬂ  iximab; ITT, intent to treat; MTX, methotrexate.
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Table 3  Changes from baseline in ACR core domains at week 16
ACR domain
Inﬂ  iximab plus 
methotrexate (n=56) Methotrexate (n=54) p Value
Swollen joint count, median change* –11.0 –9.0 0.0016
Tender joint count, median change* –14.0 –9.5 0.0007
Subject’s pain assessment,† mean change±SD (mm) –45.8±26.4 –23.1±20.0 <0.0001
Subject’s GAD,† mean change±SD (mm) –43.0±24.2 –24.1±22.7 <0.0001
Evaluator’s GAD,† mean change±SD (mm) –47.4±18.3 –30.6±21.6 <0.0001
HAQ–DI, mean change±SD –0.99±0.72 –0.56±0.72 0.0041
CRP, median change (mg/l) –12.0 –5.8 0.0026
ESR, median change (s) –12.0 –8.0 0.0023
*Based on raw data.
†Using VAS.
ACR, American College of Rheumatology; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GAD, global assessment of 
disease activity; HAQ–DI, health assessment questionnaire–disability index.
Figure 3  (A) Proportion of patients achieving indicators of profound disease suppression at week 16. All between-group differences are 
signiﬁ  cant (p<0.01). (B) Proportion of patients with minimal disease activity at each study visit. Between-group differences are signiﬁ  cant at 
weeks 6, 14 and 16. CRP, C-reactive protein; DAS28, disease activity score in 28 joints; IFX, inﬂ  iximab; MTX, methotrexate; PASI, psoriasis area 
and severity index.
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at week 14 for IMPACT 2, whereas they were less than 5% 
for placebo in both studies. In the current study, the PASI 
responses are again signiﬁ  cantly higher for both combination 
therapy and methotrexate alone.
The Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis (GRAPPA) treatment recommendations for 
PsA support the use of disease-modifying therapy in all patients 
with moderate or severe peripheral arthritis.12 Furthermore, 
the recommendations state that there is no evidence to sup-
port the use of conventional DMARD ahead of TNF inhibi-
tors and that TNF inhibitors could be considered as ﬁ  rst-line 
therapy in patients with a poor prognosis even if they have not 
failed treatment with a standard DMARD.12 The EULAR rec-
ommendations for the management of PsA are more conserva-
tive.29 While noting that few studies have investigated the use 
of DMARD in PsA, they recommend that patients with active 
disease despite NSAID receive a DMARD ‘early’ (ie, a few 
weeks to 1 year) and methotrexate is the ﬁ  rst choice. Upon 
DMARD failure and non-achievement of target low-disease 
activity, TNF inhibitors may be considered in patients with 
still-active disease.
In the present study, the high ACR20 and PASI75 response 
rates in methotrexate-alone patients support GRAPPA and 
EULAR recommendations to use methotrexate in active PsA.12 
29 In light of the paucity of data for methotrexate and con-
sidering the severity of the population, this study provides 
important new evidence further establishing the efﬁ  cacy of 
this DMARD in PsA. Differences between the inﬂ  iximab plus 
methotrexate and methotrexate-alone groups were larger when 
more difﬁ  cult to achieve outcomes such as ACR50, ACR70 and 
MDA were evaluated. This supports the GRAPPA recommen-
dation to use combination therapy including an anti-TNF agent 
in poor-prognosis patients even if methotrexate alone has not 
been tried.12
Until now, there has been little evidence for any treatment 
providing effective relief for dactilitis and enthesitis associ-
ated with PsA. GRAPPA suggests that high-quality evidence 
is available only for TNF inhibitors in the treatment of severe 
enthesitis and dactylitis, and at present inﬂ  iximab is the only 
TNF inhibitor recommended for the treatment of dactyli-
tis on the basis of available evidence.12 Our study supports 
this recommendation and demonstrates that inﬂ  iximab plus 
that had not been noted earlier. The patient was reportedly well 
approximately 5 weeks after discharge.
Other AE leading to discontinuation in the inﬂ  iximab plus 
methotrexate group included generalised oedema, pain, pyrexia, 
folliculitis, upper respiratory tract infection, dyspnoea and blood 
bilirubin increase (two patients). In the methotrexate-alone 
group, AE leading to discontinuation included diarrhoea, gastri-
tis, nausea, vomiting and dizziness.
DISCUSSION
The IMPACT studies demonstrated that inﬂ   iximab with or 
without methotrexate is efﬁ  cacious for the treatment of active 
PsA in patients with an insufﬁ  cient response to conventional 
therapy.21–24 The present open-label study compared the use of 
inﬂ  iximab plus methotrexate with methotrexate alone in meth-
otrexate-naive patients with PsA. A greater degree of improve-
ment was demonstrated with inﬂ   iximab plus methotrexate 
therapy versus methotrexate monotherapy for every measure 
examined. This was an open-label study; therefore these results 
must be conﬁ  rmed in a blinded fashion.
In the ﬁ  rst IMPACT study, the mean disease duration of 
PsA was 11 years or greater and all patients had failed treat-
ment with at least one DMARD (approximately 50% had 
failed with two or more DMARD).22 In IMPACT 2, disease 
duration was approximately 8 years, 79.5% of patients had 
used at least one DMARD, and 68.5% of patients had used 
methotrexate.24 In the current study, patients had a rela-
tively short disease duration (mean duration 2.8–3.7 years), 
and the majority were naive to methotrexate and most 
other DMARD. Observed levels of baseline disease activity 
and disability were similar to those observed for IMPACT 
patients in terms of swollen joint count, tender joint count, 
disease activity score, health assessment questionnaire–dis-
ability index and patient/physician global assessments.12 In 
this earlier treatment setting there is a strikingly larger treat-
ment effect at week 14 on joints and skin. ACR20 response 
rates in the IMPACT 1 and 2 studies were 67.3% and 58.0%, 
respectively, for inﬂ  iximab (with or without methotrexate) 
and 11.3% and 11.0% for placebo, whereas they were greater 
than 80% for inﬂ  iximab plus methotrexate and greater than 
60% for methotrexate in the current study. PASI75 response 
to inﬂ  iximab was 68.0% at week 16 for IMPACT 1 and 63.9% 
Table 4  Summary of adverse events
Treatment-emergent adverse events
Inﬂ  iximab plus methotrexate 
(n=57) Methotrexate (n=54)
No of subjects (%) No of subjects (%)
Subjects with at least one AE 33 (57.9) 19 (35.2)
Subjects with serious AE 2 (3.5) 0 (0)
Subjects with severe AE 1 (1.8) 1 (1.9)
Subjects with AE leading to early withdrawal 7 (12.3) 2 (3.7)
Subjects with treatment-related AE 26 (45.6) 13 (24.1)
  Nasopharyngitis 2 (3.5) 0 (0)
  Upper abdominal pain 0 (0) 3 (5.6)
  Infusion-related reaction 2 (3.5) 0 (0)
  Fever 2 (3.5) 0 (0)
  Headache 3 (5.3) 1 (1.9)
  Leucopenia 2 (3.5) 0 (0)
Liver enzymes: mean change from baseline to week 16 (SD)
  ALT 13.8 (27.79) 13.5 (30.74)
  AST 7.43 (14.71) 3.69 (11.26)
  GGT –28.9 (202.78) 35.18 (137.40)
 Total  bilirubin 1.6 (3.70) 0.7 (5.0)
AE, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyltransferase
13_annrheumdis-2011-152223.indd   546 13_annrheumdis-2011-152223.indd   546 2/28/2012   9:11:38 PM 2/28/2012   9:11:38 PMClinical and epidemiological research
Ann Rheum Dis 2012;71:541–548. doi:10.1136/annrheumdis-2011-152223 547
Medical Suites, Kempton Park, South Africa; EM van Duuren, Jacaranda Hospital, 
Pretoria, South Africa; C Spargo, Vincent Pallotti Hospital, Pinelands, South Africa; 
I Louw, Panorama Hospital Medical Centre, Cape Town, South Africa; C Codreanu, 
Centrul de Boli, Bucharest, Romania; R Ionescu, Sp Clinic Sf Maria, Bucharest, 
Romania; RM Chireac, Sp Clinic de Recuperare, Iasi, Romania; S Rednic, Sp Clinic 
Judetean Cluj, Cluj, Romania; M Hammoudeh, Hamad Medical Corporation, Doha, 
Qatar; J Szechinski, Prywatny Gabinet Internistyczno-Reumatologiczny, Wroclaw, 
Poland; M Rell-Bakalarska, Przychodnia Przykliniczna, Warszawa, Poland; D 
Avraham, Meir MC Dermatology, Kfar Saba, Israel; D Andersone, P Stradins Clinical 
University Hospital, Riga, Latvia; P Keszthelyi, Bekes County Pandy Kalman Hospital, 
Gyula, Hungary; P Suranyi, Hajdu-Bihar County Kenezy Gyula Hospital, Debrecen, 
Hungary
Provenance and peer review  Not commissioned; externally peer reviewed.
REFERENCES
 1.  Gladman DD. Psoriatic arthritis from Wright’s era until today. J Rheumatol Suppl 
2009;83:4–8.
 2.  Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of 
life assessment. Dermatol Clin 1996;14:485–96.
 3.  Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in 
Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol 2000;27:1247–50.
 4.  Alenius GM, Stenberg B, Stenlund H, et al. Inﬂ  ammatory joint manifestations are 
prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic 
patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 
2002;29:2577–82.
 5.  Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and 
radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809–12.
 6.  Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic 
arthritis: multivariate relative risk model. J Rheumatol 1995;22:675–9.
 7.  Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008;26
(5 Suppl 51):S62–5.
 8.  Borman P, Toy GG, Babaoglu S, et al. A comparative evaluation of quality of life and 
life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol 
2007;26:330–4.
 9.  Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the 
impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 
2006;155:729–36.
10.  Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of 
psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines 
of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 
2008;58:851–64.
11.  Gladman DD. Psoriatic arthritis. Dermatol Ther 2009;22:40–55.
12.  Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for 
psoriatic arthritis. Ann Rheum Dis 2009;68:1387–94.
13.  Black RL, O’Brien WM, Vanscott EJ, et al. Methotrexate therapy in psoriatic arthritis; 
double-blind study on 21 patients. JAMA 1964;189:743–7.
14.  Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo 
controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 
1984;27:376–81.
15.  Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment 
of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in 
psoriatic arthritis trial. Arthritis Rheum 2007;56:476–88.
16.  Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis 
factor α antibody, administered every four weeks as a subcutaneous injection in 
psoriatic arthritis: 24-week efﬁ  cacy and safety results of a randomized, placebo-
controlled study. Arthritis Rheum 2009;60:976–86.
17.  Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic 
arthritis: safety, efﬁ  cacy, and effect on disease progression. Arthritis Rheum 
2004;50:2264–72.
18.  Mease P, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of 
patients with moderately to severely active psoriatic arthritis. Arthritis Rheum 
2005;52:3279–89.
19.  Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression 
in patients with psoriatic arthritis following 2 years of treatment with etanercept. 
J Rheumatol 2006;33:712–21.
20.  Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic 
arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial 
(ADEPT). Ann Rheum Dis 2009;68:702–9.
21.  Antoni C, Krueger GG, de Vlam K, et al. Inﬂ  iximab improves signs and symptoms of 
psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150–7.
22.  Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained beneﬁ  ts of inﬂ  iximab therapy 
for dermatologic and articular manifestations of psoriatic arthritis: results from the 
inﬂ  iximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 
2005;52:1227–36.
23.  Kavanaugh A, Antoni CE, Gladman D, et al. The Inﬂ  iximab Multinational Psoriatic 
Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. 
Ann Rheum Dis 2006;65:1038–43.
methotrexate is more effective than methotrexate monother-
apy, although enthesitis only differed numerically between 
the two treatment groups.
Our study has several limitations. Recruitment was slow 
and, for practical reasons, was halted before attainment of 
the target number (216 patients). The slow pace was due to 
the requirement that subjects be methotrexate naive and have 
active PsA, as deﬁ  ned by the protocol. The smaller sample 
size is a study limitation because large studies produce nar-
row conﬁ  dence intervals and more precise results. Signiﬁ  cant 
results in a small study highlight the effect size of therapy. 
Some bias is introduced because of the open-label design, as 
many of the outcome measures were self-reported and subjec-
tive or were assessed by non-blinded evaluators. This prob-
ably had an effect on the compliance with methotrexate use 
and may very well have inﬂ  ated the response rates in both 
treatment arms. Although subjective measures were used 
to assess many of the outcomes in this study, the objective 
measures, such as CRP and ESR, also signiﬁ  cantly differed 
between the treatment groups. In addition, the signiﬁ  cant 
differences between the two groups in remission/MDA out-
comes suggest robust results despite the open-label design. It 
is possible that a longer study period and better compliance 
with treatment would have revealed increasing efﬁ  cacy  of 
methotrexate. Conﬁ  rmation of methotrexate efﬁ  cacy in this 
population via a blinded, placebo-controlled study and com-
parison of inﬂ  iximab and methotrexate monotherapies clearly 
merit additional research.
Inﬂ  iximab plus methotrexate treatment was generally well 
tolerated. Although there was a higher reported incidence of AE 
and withdrawals due to AE, this was consistent with the previ-
ously reported safety proﬁ  le for inﬂ  iximab, and no new safety 
signals were observed.
The use of inﬂ   iximab plus methotrexate in methotrexate-
naive patients with PsA achieved greater improvements in all 
clinical outcomes measured than the use of methotrexate alone. 
Response was more rapid with combination therapy, and it 
accomplished profound disease suppression in a signiﬁ  cantly 
larger proportion of patients by week 16 compared with metho-
trexate monotherapy.
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